A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Relapsed/Refractory Cervical and Endometrial Cancer

Early Phase 1

Recruiting

Conditions: Endometrial Cancer
Cervical Cancer
Advanced Cancer

Interventions: Drug: Recombinant oncolytic herpes simplex virus type Ⅰ (R130)

Registration Number: NCT05812677

Lead Sponsor: Shanghai Yunying Medical Technology

Brief Summary: 20 participants are expected to be enrolled for this open，Single-armed clinical trial to evaluate the safety and efficacy of the recombinant herpes simplex virus Ⅰ, R130 in patients with relapsed/refractory Cervical and Endometrial Cancer.

Detailed Description: Not available

Recruitment & Eligibility

Status: RECRUITING

Sex: Female

Target Recruitment: 20

Inclusion Criteria

Patients with cervical cancer or endometrial cancer clearly diagnosed by histology and/or cytology.
Failure of standard treatment or patient unwillingness to receive other antitumor therapy.
Age 18 to 75 years.
Subjects with ECoG score of 0-2.
Expected survival of 3 months or more.
Have at least one measurable lesion (according to RECIST 1.1 criteria) that is amenable to intratumoral or intraperitoneal drug delivery.
Subjects must have appropriate organ function, and laboratory tests during the screening period must meet the following requirements: a) absolute neutrophil count (ANC) ≥ 1.5 × 109/L, platelets (PLT) ≥ 80 × 109/L, and hemoglobin (Hb) ≥ 85 g/L; b) serum creatinine (Cr) and blood urea nitrogen (BUN) within 1.5 times the upper limit of normal values; c) serum c) serum total bilirubin (TBIL) ≤ 2 times the upper limit of normal values; d) glutamic aminotransferase (ALT) and glutamic oxalacetic aminotransferase (AST) ≤ 2.5 times the upper limit of normal values; subjects with liver metastases do not exceed 5 times the upper limit of normal values; e) activated partial thromboplastin time (APTT), prothrombin time (PT) within 1.5 times the upper limit of normal values.
Any treatment for malignancy, including radiotherapy, chemotherapy and biological agents, must be discontinued 28 days prior to R130 treatment.
Eligible patients of childbearing potential must agree to use a reliable method of contraception (hormonal or barrier method or abstinence) with their partner for the duration of the trial and for at least 180 days after the last dose; female patients of childbearing potential must have a negative urine pregnancy test within 7 days prior to enrollment.
Subjects voluntarily sign an informed consent form and are in good compliance.

Exclusion Criteria

Have had any serious adverse reactions associated with immunotherapy.
Subjects with any severe and/or uncontrolled disease, including: a) poorly controlled hypertension (systolic blood pressure ≥ 150 mmHg or diastolic blood pressure ≥ 100 mmHg); b) suffering from class I or higher myocardial ischemia or myocardial infarction, arrhythmia (QTc ≥ 470 ms and ≥ grade 2 congestive heart failure (New York Heart Association (NYHA) classification); c) active or uncontrolled severe infection (≥ CTCAE grade 2 infection); d) Patients with previous organ transplantation, bone marrow transplantation (hematopoietic stem cell transplantation) and severe immune deficiency; e) Urine routine suggesting urine protein ≥++ and confirmed 24-hour urine protein quantification > 1.0 g.
Patients with past history of type I diabetes mellitus or HIV.
Severe abnormalities in thyroid and cortisol testing; active, known or suspected autoimmune disease requiring systemic therapy.
Patients with symptomatic primary or metastatic brain tumors.
Patients with active tuberculosis and a strong positive OT test.
Patients with active bleeding or severe coagulation dysfunction.
Have had antitumor therapy, including endocrine, chemotherapy, radiotherapy, targeted therapy, immunotherapy and antitumor herbal therapy, 4 weeks prior to the first dose.
Have not recovered to CTCAE 5.0 grade rating 0 or 1 level of toxicity after previous antineoplastic therapy.
Current active hepatitis B, active hepatitis C, immunodeficiency virus or other active infection of clinical significance.
Patients who have undergone surgery of grade 3 or higher or whose surgical wounds have not healed within 4 weeks prior to enrollment.
Participation in other clinical trials within four weeks prior to enrollment.
Subjects who, in the judgment of the investigator, are unsuitable for participation in this trial for any reason.

Study & Design

Study Type: INTERVENTIONAL

Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
R130 Treatment Group	Recombinant oncolytic herpes simplex virus type Ⅰ (R130)	Every 7-14 days,1-4 ml R130 （concentration of 1x10\^8 plaque-forming Units/mL,PFU/mL）will be injected intratumoral or Intraperitioneal in patients with relapsed/refractory cervical and endometrial Cancer.

Primary Outcome Measures

Name	Time	Method
Adverse Events	Up to 6 months	All serious and non-serious adverse events that occur after enrollment through 7 (+14) days after the last administration of R130 will be recorded
Systemic immune response	Up to 6 months	Detection of increased systemic immune Response markers in sera,ascites and peripheral blood mononuclear cells by multi-Color fluorescence-activated cell sorting (FACS)

Secondary Outcome Measures

Name	Time	Method
Quality of Life Assessment	Every 6 weeks for 12 months	Evaluate with EORTC QLQ-C30
Disease Assessment for Disease Control Rate	Every 10 weeks for 12 months	Evaluate the efficacy endpoints of DCR by the investigator with RECIST v1.1 and iRECIST
Disease Assessment for Duration of Response	Every 10 weeks for 12 months	Evaluate the efficacy endpoints of DOR by the investigator with RECIST v1.1 and iRECIST

Trial Locations

Locations (1): Shanghai Tenth People's Hospital
🇨🇳
Shanghai, Shanghai, China